HBI-3000: A Novel anti-arrhythmic compound
-
Multi-ion channel blocker like amiodarone and dronedarone (Multaq®) with low pro-arrhythmic activity in “gold standard” animal models and pharmacology studies ongoing in the US
-
Well tolerated in Chinese Phase 1 studies
-
Oral and iv formulations developed with potential for use in both acute and recurrent atrial fibrillation as well as ventricular arrhythmias - one of the few remaining candidate treatments for acute cardioversion
-
Successful Pre-IND meeting with US FDA: Plan approved including use of Chinese clinical data
-
Phase 2 in China in progress; protocol designed in partnership with HUYA
About Anti-Arrhythmic drugs
Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases they carry significant safety risk. The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease, precluding treatment with most existing anti-arrhythmic drugs for a majority of patients. Development of safe anti-arrhythmic agents is needed. Data suggest that HBI-3000 may have safety advantages over other anti-AF agents and may also have potential for use in treating ventricular arrhythmias. Worldwide licensing rights ex-China are available for HBI-3000.